226 related articles for article (PubMed ID: 15651744)
1. Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms.
Nolan D; Mallal S
Antivir Ther; 2004 Dec; 9(6):849-63. PubMed ID: 15651744
[TBL] [Abstract][Full Text] [Related]
2. Long-term complications of nucleoside reverse transcriptase inhibitor therapy.
Dieterich DT
AIDS Read; 2003 Apr; 13(4):176-84, 187. PubMed ID: 12741368
[TBL] [Abstract][Full Text] [Related]
3. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity.
Moyle G
Clin Ther; 2000 Aug; 22(8):911-36; discussion 898. PubMed ID: 10972629
[TBL] [Abstract][Full Text] [Related]
4. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease.
Vigouroux C; Gharakhanian S; Salhi Y; Nguyên TH; Adda N; Rozenbaum W; Capeau J
Diabetes Metab; 1999 Nov; 25(5):383-92. PubMed ID: 10592860
[TBL] [Abstract][Full Text] [Related]
5. Hyperlactataemia in HIV-infected patients: the role of NRTI-treatment.
Vrouenraets SM; Treskes M; Regez RM; Troost N; Smulders YM; Weigel HM; Frissen PH; Brinkman K
Antivir Ther; 2002 Dec; 7(4):239-44. PubMed ID: 12553477
[TBL] [Abstract][Full Text] [Related]
6. Update on mitochondrial toxicity of antiretrovirals and its link to lipodystrophy.
McComsey G
AIDS Rev; 2002; 4(3):140-7. PubMed ID: 12416448
[TBL] [Abstract][Full Text] [Related]
7. The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome.
Nolan D; Mallal S
J HIV Ther; 2004 May; 9(2):34-40. PubMed ID: 15238874
[TBL] [Abstract][Full Text] [Related]
8. Polyphenotypic expression of mitochondrial toxicity caused by nucleoside reverse transcriptase inhibitors.
Miller RF; Shahmonesh M; Hanna MG; Unwin RJ; Schapira AH; Weller IV
Antivir Ther; 2003 Jun; 8(3):253-7. PubMed ID: 12924544
[TBL] [Abstract][Full Text] [Related]
9. Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy.
Calza L; Manfredi R; Chiodo F
Clin Nutr; 2005 Feb; 24(1):5-15. PubMed ID: 15681097
[TBL] [Abstract][Full Text] [Related]
10. HIV and mitochondrial toxicity in children.
Foster C; Lyall H
J Antimicrob Chemother; 2008 Jan; 61(1):8-12. PubMed ID: 17999978
[TBL] [Abstract][Full Text] [Related]
11. [Impact of reverse transcriptase inhibitors on sperm mitochondrial and genomic DNA in assisted reproduction techniques].
Sergerie M; Martinet S; Kiffer N; Teulé R; Pasquier C; Bujan L
Gynecol Obstet Fertil; 2004 Oct; 32(10):841-9. PubMed ID: 15501159
[TBL] [Abstract][Full Text] [Related]
12. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
Joly V; Yeni P
Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
[TBL] [Abstract][Full Text] [Related]
13. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.
Kakuda TN
Clin Ther; 2000 Jun; 22(6):685-708. PubMed ID: 10929917
[TBL] [Abstract][Full Text] [Related]
14. Asymptomatic hyperlactataemia: predictive value, natural history and correlates.
McComsey GA; Yau L
Antivir Ther; 2004 Apr; 9(2):205-12. PubMed ID: 15134182
[TBL] [Abstract][Full Text] [Related]
15. A brief overview of mechanisms of mitochondrial toxicity from NRTIs.
Kohler JJ; Lewis W
Environ Mol Mutagen; 2007; 48(3-4):166-72. PubMed ID: 16758472
[TBL] [Abstract][Full Text] [Related]
16. Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.
Nolan D; John M; Mallal S
Antivir Ther; 2001 Sep; 6(3):145-60. PubMed ID: 11808750
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral therapy affects the composition of weight loss in HIV infection: implications for clinical nutrition.
Maia BS; Engelson ES; Wang J; Kotler DP
Clin Nutr; 2005 Dec; 24(6):971-8. PubMed ID: 16095765
[TBL] [Abstract][Full Text] [Related]
18. [Metabolic side effects of antiretroviral therapy].
van der Valk M; Reiss P
Ned Tijdschr Geneeskd; 2008 May; 152(22):1260-4. PubMed ID: 18590059
[TBL] [Abstract][Full Text] [Related]
19. Update on mitochondrial toxicity: where are we now?
Walker UA
J HIV Ther; 2003 May; 8(2):32-5. PubMed ID: 12838162
[TBL] [Abstract][Full Text] [Related]
20. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]